Clinical evaluation of neurotropin in the treatment of sequelae of subacute myelo-optico-neuropathy — a double-blind cross-over study

Neurotropin® alleviates hippocampal neuron damage through a HIF‐1α/MAPK pathway

“…Neurotropin ® (NTP), a nonprotein extract from inflamed rabbit skin inoculated with vaccinia virus, is a well-known analgesic drug for treatment of chronic pain, such as low back pain, postherpetic neuralgia, neck-shoulder-arm syndrome, hyperesthesia of subacute myelo-optic neuropathy (SMON), and fibromyalgia. [2][3][4][5] Recently, it is reported that NTP-stimulated BDNF expression in SH-SY5Y cells, and repeated oral administration of NTP (200 NU/kg/d for 3 months) inhibited the decline of hippocampal BDNF expression, accompanied by improvement in spatial cognition of Ts65Dn mice, a model of Down syndrome. 6 Furthermore, Nakajo et al 7 demonstrated that chronic NTP treatment reduced the volumes of infracted lesions, brain edema, and the extent of the neurological deficits, and also enhanced spatial learning of C57BL/6J mice.…”